title: Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers.
abstract: OBJECTIVE
  A nation-wide prevention program utilizing passive-active immunoprophylaxis for high-risk babies against maternal HBV transmission was introduced in Japan in January of 1986. The prevention program was expected to eradicate HBV-related hepatocellular carcinoma (HCC). The aim of this study was to evaluate the effect of this selective prevention program against maternal HBV transmission on the occurrence of HBV-related HCC.
  
  
  METHODS
  We reviewed the annual reports from a nation-wide survey of childhood solid tumors that was reported in the Journal of the Japanese Society of Pediatric Surgeons during the 28 years period from 1981 to 2008. The number of HCC cases were grouped for every 5-year period with an additional period of the past 3 years and compared with those of hepatoblastoma.
  
  
  RESULTS
  The reported number of children with hepatoblastoma in each period was constant during the 28 years study period. In contrast, both the number of patients with HBV-related HCC and the ratio of HBV-related HCC to hepatoblastoma gradually decreased over the study period, with a significant drop in the last two periods ranging from 2001 to 2008 (p < 0.001).
  
  
  CONCLUSIONS
  The prevention program against maternal HBV infection of infants born to HBV carrier mothers may have decreased the occurrence of HBV-related HCC in childhood.
authors.affiliation: Department of Paediatrics, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-ku, Osaka 558-8558, Japan. tajiriji@gh.opho.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tajiri
authors.forename: Hideo
authors.initials: H
authors.lastname: Tanaka
authors.forename: Stephen
authors.initials: S
authors.lastname: Brooks
authors.forename: Tomoko
authors.initials: T
authors.lastname: Takano
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D002353:Carrier State / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D002648:Child; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D018197:Hepatoblastoma / Q000276:immunology; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D009035:Mothers; D009369:Neoplasms / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012306:Risk; D014611:Vaccination
chemical_list: D017325:Hepatitis B Vaccines